Clinical trials: Hepatotoxicity
- Condition Hepatotoxicity
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Infection, Human Immunodeficiency Virus I
PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)
Dolutegravir (DTG) is recommended for both treatment-naïve and treatment-experienced, HIV infected adults and paediatric subjects aged 12 years and older and weighing at least 40 kg.
- Trial name
- NCT03327740
- Testing
- DTG based ARV regimen with ABC, DTG based ARV regimen without ABC, RAL or EGV based ARV regimens with ABC
- Volunteers
- 1 people
- Sponsor
- ViiV Healthcare
Acetaminophen Overdose
Safety and Efficacy Study of a New Formulation of Acetylcysteine Injection
The primary purpose of this study is determine if a new formulation of Acetadote is at least as effective as the current formulation in the prevention and treatment of acetaminophen overdose related liver injury.
- Trial name
- NCT01118663
- Testing
- Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free), Acetadote
- Where
- 14 sites in United States
- Volunteers
- 17 people
- Sponsor
- Cumberland Pharmaceuticals
Breast Cancer
Liver Safety Under Upfront Arimidex vs Tamoxifen
The primary objective is to compare ARIMIDEX (anastrozole) 1 mg once daily with Tamoxifen 20 mg once daily as adjuvant treatment in terms of: incidence of fatty liver diseases.
- Trial name
- HEART (NCT00537771)
- Testing
- Anastrozole, Tamoxifen
- Where
- 16 sites in China
- Volunteers
- 384 people
- Sponsor
- AstraZeneca